This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
==== Skin conditions ==== UV rays also treat certain skin conditions. Modern phototherapy has been used to successfully treat psoriasis, eczema, jaundice, vitiligo, atopic dermatitis, and localized scleroderma. In addition, UV radiation, in particular UVB radiation, has been shown to induce cell cycle arrest in keratinocytes, the most common type of skin cell. As such, sunlight therapy can be a candidate for treatment of conditions such as psoriasis and exfoliative cheilitis, conditions in which skin cells divide more rapidly than usual or necessary.
While the term embalming is used for both ancient and modern methods of preserving a deceased person, there is very little connection between the modern-day practices of embalming and ancient methods in terms of techniques or final aesthetic results. The Chinchorro culture in the Atacama desert of present-day Chile and Peru is among the earliest cultures known to have performed artificial mummification, as early as 5000–6000 BCE. The earliest known evidence of artificial preservation in Europe was found in Osorno (Spain) – approximately 5000-year-old human bones covered in cinnabar for preservation – however embalming remained unusual in Europe up to the time of the Roman Empire. Evidence of embalming practices in Egypt date to at least 3500 BCE. Ritual mummification, including embalming, continued to develop into a standardized practice in the dynastic period, and typically involved removing organs, ridding the body of moisture, and covering the body with natron, a mixture of desiccating salts found naturally in the Wadi El Natrun west of the Nile Delta. The ancient Egyptians believed that mummification enabled the soul to return to the preserved corpse after death. Other cultures known to have used embalming techniques in antiquity include the Meroites, Guanches, Peruvians, Jivaro Indians, Aztecs, Toltecs, Mayans, and Tibetan and southern Nigerian tribes. In China, artificially preserved remains have been recovered from the period of the Han dynasty (206 BCE–220 CE), the main examples being those of Xin Zhui and the Mawangdui Han tombs site.
An individual who both initiates and conducts, alone or with others, a clinical trial, and under whose immediate direction the investigational product is administered to, dispensed to, or used by a subject. The term does not include any person other than an individual (e.g., it does not include a corporation or an agency). The obligations of a sponsor-investigator include both those of a sponsor and those of an investigator. (ICH E6) An individual who both initiates and actually conducts, alone or with others, a clinical investigation, i.e., under whose immediate direction the test article is administered or dispensed to, or used involving, a subject. The term does not include any person other than an individual, e.g., corporation or agency. (21CFR50.3) Standard treatment
==== Carbohydrates ==== The principal soluble carbohydrates of mature soybeans are the disaccharide sucrose (range 2.5–8.2%), the trisaccharide raffinose (0.1–1.0%) composed of one sucrose molecule connected to one molecule of galactose, and the tetrasaccharide stachyose (1.4 to 4.1%) composed of one sucrose connected to two molecules of galactose. While the oligosaccharides raffinose and stachyose protect the viability of the soybean seed from desiccation (see above section on physical characteristics) they are not digestible sugars, so contribute to flatulence and abdominal discomfort in humans and other monogastric animals, comparable to the disaccharide trehalose. Undigested oligosaccharides are broken down in the intestine by native microbes, producing gases such as carbon dioxide, hydrogen, and methane. Since soluble soy carbohydrates are found in the whey and are broken down during fermentation, soy concentrate, soy protein isolates, tofu, soy sauce, and sprouted soybeans are without flatus activity. On the other hand, there may be some beneficial effects to ingesting oligosaccharides such as raffinose and stachyose, namely, encouraging indigenous bifidobacteria in the colon against putrefactive bacteria. The insoluble carbohydrates in soybeans consist of the complex polysaccharides cellulose, hemicellulose, and pectin. The majority of soybean carbohydrates can be classed as belonging to dietary fiber.
buffered solution Also simply called a buffer. An aqueous solution consisting of a weak acid and its conjugate base or a weak base and its conjugate acid that resists changes in pH when strong acids or bases are added.
Sources: en.wikipedia.org
== Cell cycle regulation == The eukaryotic cell cycle is regulated through the synthesis, degradation, binding interactions, post-translational modifications of regulatory proteins. Of these regulatory proteins, two ubiquitin ligases are crucial for progression through cell cycle checkpoints. The anaphase-promoting complex (APC) controls the metaphase-anaphase transition, while the SCF complex controls G1/S and G2/M transitions. Specifically, SCF has been shown to regulate centriole splitting from late telophase to the G1/S transition. SCF activity is largely regulated by post-translational modifications. For instance, ubiquitin-mediated autocatalytic degradation of FBPs is a mechanism of decreasing SCF activity. Well-characterized cell cycle substrates of SCF complexes include:
=== Immigration Act of 1924 === Anti-miscegenation laws, along with the Immigration Act of 1924, contributed to the anti-immigrant sentiment that existed during the development of United States history. At this point in time, the United States was concerned with foreigners coming into the country in higher numbers and therefore enforced its first border patrol and regulated the number of foreign immigrants from south and eastern Europe, as well as permitting people from the southern people specialized in agriculture and work from the southern border. In the forgotten narrative of Latin American History, U.S., Mexican immigrants and citizens were labeled and seen as a problem in society because they were seen as hyper-fertile and supported theories that Mexicans were of a lower racial level. By the first half of the 20th century, almost 60,000 people had been sterilized under the different U.S. Eugenics Programs implemented.
== Factors == First-pass metabolism may occur in the liver (for propranolol, lidocaine, clomethiazole, and nitroglycerin) or in the gut (for benzylpenicillin and insulin). The four primary systems that affect the first pass effect of a drug are the enzymes of the gastrointestinal lumen, gastrointestinal wall enzymes, bacterial enzymes and hepatic enzymes.
==== Chile ==== Cider has been made in Chile since colonial times. Southern Chile accounts for nearly all cider production in the country. Chileans make a distinction between "sidra" ("cider"), in fact, sparkling cider, and "chicha de manzana" ("apple chicha"), a homemade cider that is considered of less quality.
== Further reading == Archives National Library of Scotland, correspondence and papers The National Archives Public Record Office (TNA: PRO), reports on Germany, MH79/358 National Archives of Scotland, correspence with Lord Lothian Rowett Research Institute, Aberdeenshire, corresp. and papers relating to Rowett Research Institute Likenesses from the National Portrait Gallery Lida Moser, photograph, 1949, National Portrait Gallery (NPG) [see illus.] B. Schotz, bronze head, 1950, Hunterian Museum and Art Gallery, Glasgow W. Stoneman, bromide print, 1953, NPG Elliott & Fry, photograph, NPG Elliott & Fry, vintage print, 1942, NPG photograph, repro. in Kay, Memoirs FRS Hansard 1803–2005: contributions in Parliament by John Boyd Orr
Sources: en.wikipedia.org
Soon after Atal Bihari Vajpayee became Indian prime minister, he authorised nuclear weapons testing at Pokhran. The United States strongly condemned this testing, promised sanctions, and voted in favor of a United Nations Security Council resolution condemning the tests. President Bill Clinton imposed economic sanctions on India, including cutting off all military and economic aid, freezing loans by American banks to state-owned Indian companies, prohibiting loans to the Indian government for all except food purchases, prohibiting American aerospace technology and uranium exports to India, and requiring the US to oppose all loan requests by India to international lending agencies. However, these sanctions proved ineffective – India was experiencing a strong economic rise, and its trade with the US only constituted a small portion of its GDP. Only Japan joined the US in imposing direct sanctions, while most other nations continued to trade with India. The sanctions were soon lifted. Afterward, the Clinton administration and Prime Minister Vajpayee exchanged representatives to help rebuild relations. In March 2000, Clinton visited India, undertaking bilateral and economic discussions with Vajpayee. This would mark the first U.S. presidential trip to India since 1978. During the visit, the Indo-US Science & Technology Forum was established. Over the course of improved diplomatic relations with the Bush administration, India agreed to allow close international monitoring of its nuclear weapons development, although it has refused to give up its current nuclear arsenal.
==== Suicides ==== On January 17, 2020, a video titled "Medical Help" was uploaded to YouTube by 26-year-old Wail Ardab of Palatka, Florida, who developed dystonia and insomnia after taking Invega Trinza injections. On March 5, 2020, Ardab committed suicide by jumping from Memorial Bridge in Palatka. From June 2023 to April 2024, Serbian television presenter and journalist Bojana Nikolić Janković posted to the internet forum Bluelight that she received 4 shots of Invega Sustenna and 2 shots of Invega Trinza due to the stress of her divorce from Ognjen Janković, a member of the hip-hop group Beogradski Sindikat. Janković, known for hosting the show City, wrote that she was bedridden with persistent anhedonia, cognitive issues, low energy and other symptoms consistent with neuroleptic-induced deficit syndrome after receiving the injections. She died in Belgrade on April 19, 2024, at age 46.
== Context == Selection acts on variation in phenotypes, which are often the result of mutations in protein-coding genes. The genetic code is written in DNA sequences as codons, groups of three nucleotides. Each codon represents a single amino acid in a protein chain. However, there are more codons (64) than amino acids found in proteins (20), so many codons are effectively synonyms. For example, the DNA codons TTT and TTC both code for the amino acid Phenylalanine, so a change from the third T to C makes no difference to the resulting protein. On the other hand, the codon GAG codes for Glutamic acid while the codon GTG codes for Valine, so a change from the middle A to T does change the resulting protein, for better or (more likely) worse, so the change is not a synonym. These changes are illustrated in the tables below. The Ka/Ks ratio measures the relative rates of synonymous and nonsynonymous substitutions at a particular site.
=== Separation methods === Since astatine is the main product of the synthesis, after its formation it must only be separated from the target and any significant contaminants. Several methods are available, "but they generally follow one of two approaches—dry distillation or [wet] acid treatment of the target followed by solvent extraction." The methods summarized below are modern adaptations of older procedures, as reviewed by Kugler and Keller. Pre-1985 techniques more often addressed the elimination of co-produced toxic polonium; this requirement is now mitigated by capping the energy of the cyclotron irradiation beam.
General Cao, L. (2014). Behavior Informatics: A New Perspective. IEEE Intelligent Systems (Trends and Controversies), 29(4): 62–80. Clemons, E. K. (2008). "How Information Changes Consumer Behavior and How Consumer Behavior Determines Corporate Strategy". Journal of Management Information Systems. 25 (2): 13–40. doi:10.2753/mis0742-1222250202. S2CID 16370526. Dowhan, D (2013). "Hitting Your Target". Marketing Insights. 35 (2): 32–38. Perner, L. (2008), Consumer behavior. University of Southern California, Marshall School of Business. Retrieved from http://www.consumerpsychologist.com/intro_Consumer_Behavior.html Szwacka-Mokrzycka, J (2015). "TRENDS IN CONSUMER behavior CHANGES. OVERVIEW OF CONCEPTS". Acta Scientiarum Polonorum. Oeconomia. 14 (3): 149–156.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.